Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study
Overview
Authors
Affiliations
Background: The epidermal growth factor receptor (EGFR) amplification status of isocitrate dehydrogenase-wild-type (IDHwt) lower-grade gliomas (LGGs; grade II/III) is one of the key markers for diagnosing molecular glioblastoma. However, the association between EGFR status and imaging parameters is unclear.
Objective: To identify noninvasive imaging parameters from diffusion-weighted and dynamic susceptibility contrast imaging for predicting the EGFR amplification status of IDHwt LGGs.
Methods: A total of 86 IDHwt LGG patients with known EGFR amplification status (62 nonamplified and 24 amplified) from 3 tertiary institutions were included. Qualitative and quantitative imaging features, including histogram parameters from apparent diffusion coefficient (ADC), normalized cerebral blood volume (nCBV), and normalized cerebral blood flow (nCBF), were assessed. Univariable and multivariable logistic regression models were constructed.
Results: On multivariable analysis, multifocal/multicentric distribution (odds ratio [OR] = 11.77, P = .006), mean ADC (OR = 0.01, P = .044), 5th percentile of ADC (OR = 0.01, P = .046), and 95th percentile of nCBF (OR = 1.24, P = .031) were independent predictors of EGFR amplification. The diagnostic performance of the model with qualitative imaging parameters increased significantly when quantitative imaging parameters were added, with areas under the curves of 0.81 and 0.93, respectively (P = .004).
Conclusion: The presence of multifocal/multicentric distribution patterns, lower mean ADC, lower 5th percentile of ADC, and higher 95th percentile of nCBF may be useful imaging biomarkers for EGFR amplification in IDHwt LGGs. Moreover, quantitative imaging biomarkers may add value to qualitative imaging parameters.
Byeon Y, Park Y, Lee S, Park D, Shin H, Han K NPJ Digit Med. 2025; 8(1):140.
PMID: 40044878 PMC: 11883078. DOI: 10.1038/s41746-025-01530-4.
Vollmuth P, Karschnia P, Sahm F, Park Y, Ahn S, Jain R Korean J Radiol. 2025; 26(3):246-268.
PMID: 39999966 PMC: 11865903. DOI: 10.3348/kjr.2024.0982.
Shin I, Park Y, Sim Y, Choi S, Ahn S, Chang J Acta Neuropathol Commun. 2024; 12(1):128.
PMID: 39127694 PMC: 11316408. DOI: 10.1186/s40478-024-01832-w.
Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.
Lee M, Karschnia P, Park Y, Choi K, Han K, Choi S J Neurooncol. 2024; 169(3):531-541.
PMID: 39115615 DOI: 10.1007/s11060-024-04737-9.
Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
Liang Q, Jing H, Shao Y, Wang Y, Zhang H Clin Neuroradiol. 2024; 34(1):33-43.
PMID: 38277059 DOI: 10.1007/s00062-023-01375-y.